文献速递消化系统肿瘤

卡瑞利珠单抗联合阿帕替尼对比索拉非尼一线治疗不可切除肝细胞癌的最终分析

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
PubMed 文献 · Lancet Oncol · 2025-01-01

CARES-310是一项随机、开放、国际多中心3期试验,纳入543例不可切除肝细胞癌患者,比较卡瑞利珠单抗联合阿帕替尼与索拉非尼一线治疗。

要点

  • 卡瑞利珠单抗联合阿帕替尼一线治疗不可切除肝细胞癌显著改善总生存期和无进展生存期。
  • 联合组最常见≥3级治疗相关不良事件为高血压、掌跖红肿综合征和转氨酶升高。
  • 联合组治疗相关严重不良事件发生率25%,治疗相关死亡1例。

核心结论

  • 最终分析显示卡瑞利珠单抗联合阿帕替尼对比索拉非尼持续显示具有临床意义的生存获益,安全性可控。

研究设计与样本

  • 随机、开放、国际3期试验(CARES-310),在13个国家和地区95个中心进行,共随机543例患者(联合组272例,索拉非尼组271例)。
  • 入组标准为年龄≥18岁、不可切除或转移性肝细胞癌、未接受过系统治疗、ECOG PS 0或1。
  • 患者按1:1随机接受卡瑞利珠单抗200 mg静脉每2周联合阿帕替尼250 mg口服每日一次,或索拉非尼400 mg口服每日两次。

关键数值与推荐

  • 联合组最常见≥3级治疗相关不良事件:高血压104例(38%)、掌跖红肿综合征33例(12%)、天冬氨酸氨基转移酶升高47例(17%)、丙氨酸氨基转移酶升高38例(14%)。
  • 索拉非尼组对应不良事件:高血压40例(15%)、掌跖红肿综合征42例(16%)、天冬氨酸氨基转移酶升高14例(5%)、丙氨酸氨基转移酶升高8例(3%)。
  • 联合组治疗相关严重不良事件69例(25%),索拉非尼组18例(7%)。
  • 联合组治疗相关死亡1例(多器官功能障碍综合征),索拉非尼组1例(呼吸衰竭和循环衰竭)。

临床怎么用

  • 卡瑞利珠单抗联合阿帕替尼可作为不可切除肝细胞癌新的一线治疗选择。
  • 治疗期间需监测高血压、掌跖红肿综合征和肝功能等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 CARES-310 trial showed significant improvements in progression-free survival (primary analysis) and overall survival (interim analysis) with the anti-PD-1 antibody camrelizumab plus the oral vascular endothelial growth factor receptor 2 inhibitor rivoceranib versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Here, we present the final analysis of overall survival, and updated data on progression-free survival, secondary efficacy endpoints, and safety. METHODS: This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions. Eligible patients were aged 18 years or older, with unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Participants were randomly assigned (1:1) using a centralised interactive response system to receive either camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily or sorafenib 400 mg orally twice daily. The primary endpoints were progression-free survival, as assessed by the blinded independent review committee per Response Evaluation Criteria in Solid Tumours version 1.1, and overall survival, assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of the study drugs. The study is complete and was registered with ClinicalTrials.gov, NCT03764293. FINDINGS: Between June 28, 2019, and March 24, 2021, 543 patients (457 [84%] males; 450 [83%] were Asian) were randomly assigned to receive camrelizumab-rivoceranib (n=272) or sorafenib (n=271). At final analysis on June 14, 2023, the median follow-up was 22·1 months (IQR 11·9-30·3) in the camrelizumab-rivoceranib group and 14·9 months (7·2-28·3) in the sorafenib group. Median overall survival was 23·8 months (95% CI 20·6-27·2) with camrelizumab-rivoceranib and 15·2 months (13·2-18·5) with sorafenib (hazard ratio [HR] 0·64 [95% CI 0·52-0·79]; one-sided p<0·0001). Median progression-free survival was 5·6 months (95% CI 5·5-7·4) with camrelizumab-rivoceranib and 3·7 months (3·1-3·7) with sorafenib (HR 0·54 [0·44-0·67]; one-sided p<0·0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (104 [38%] of 272 patients in the camrelizumab-rivoceranib group vs 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs 42 [16%]), increased aspartate aminotransferase (47 [17%] vs 14 [5%]), and increased alanine aminotransferase (38 [14%] vs eight [3%]). Treatment-related serious adverse events were reported in 69 (25%) of 272 patients in the camrelizumab-rivoceranib group and 18 (7%) of 269 patients in the sorafenib group. Treatment-related deaths occurred in one patient each in the camrelizumab-rivoceranib group (multiple organ dysfunction syndrome) and sorafenib group (respiratory failure and circulatory collapse). INTERPRETATION: At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma. FUNDING: Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Qin S, Gu S, Chan SL, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. Lancet Oncol. 2025. PMID: 41308676. doi:10.1016/S1470-2045(25)00543-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。